Siglec-15与PD-1阻断联合溶瘤寨卡病毒可防护免疫抵抗性胶质瘤
研究在人类GBM样本中检测Siglec-15表达,并在同源胶质瘤模型中测试抗Siglec-15抗体、Siglec-15敲除联合寨卡病毒(ZIKV)与抗PD-1治疗。结果显示联合治疗提高长期生存率并增强CD8+ T细胞应答,提示靶向Siglec-15可克服髓系免疫抑制。
要点
- 人GBM髓系细胞与肿瘤细胞表达Siglec-15,高表达与更短生存相关。
- ZIKV联合抗Siglec-15及抗PD-1在胶质瘤小鼠中提高长期生存率。
- 联合治疗增强CD8+ T细胞活化与记忆扩增,支持进一步研究。
核心结论
- 靶向Siglec-15联合PD-1阻断与ZIKV可克服GBM髓系免疫抑制,增强T细胞活化并促进持久抗肿瘤免疫。
研究设计与样本
- 研究采用流式细胞术、质谱流式、免疫荧光及公共数据库评估人GBM样本Siglec-15表达,并在同源胶质瘤模型中使用抗Siglec-15阻断抗体、Siglec-15敲除小鼠联合ZIKV与抗PD-1治疗。
主要发现
- 人GBM髓系细胞Siglec-15表达为16-22%,肿瘤细胞为18-19%,高表达与更短生存相关。
- CT2A荷瘤小鼠中ZIKV+抗Siglec-15长期生存率60%(ZIKV单药40%),加抗PD-1升至83%。
- SB28荷瘤小鼠三联治疗长期生存率76%,CD8+ T细胞活化提高1.7倍。
- 再攻击小鼠脑内驻留/效应记忆CD8+ T细胞扩增11倍,生存率80%。
- 髓系细胞Siglec-15缺失增强吞噬(CT2A 25%;SB28 7%)与T细胞应答(活化81%;增殖86.8%)。
临床怎么用
- 这些临床前结果提示Siglec-15阻断联合PD-1阻断与溶瘤ZIKV可能成为GBM候选联合策略,尚需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: : The glioblastoma (GBM) immunosuppressive tumor microenvironment is a clinical challenge. Oncolytic Zika virus (ZIKV) has emerged as a promising therapy, targeting treatment-resistant glioma stem cells, stimulating CD8+ T-cell-mediated immunity and extends survival in preclinical models but myeloid cell-driven immunosuppression persists. An antagonist of Siglec-15, a myeloid immune checkpoint molecule, is in a phase II trial for non-small cell lung cancer, but its role in CNS malignancies remains unclear. METHODS: : We evaluated Siglec-15 expression in human GBM samples using flow cytometry, mass cytometry, and immunofluorescence, as well as a public database. Using syngeneic glioma models, we tested a blocking antibody against Siglec-15, and Siglec-15 knock out mice, alongside ZIKV and anti-PD-1 therapies. We performed survival studies and analyzed immune responses, T-cell proliferation and phagocytosis, and tumor rechallenge. RESULTS: : Siglec-15 was expressed by human GBM myeloid (16-22%) and tumor (18-19%) cells, and higher expression was associated with shorter survival. In CT2A-bearing mice, ZIKV + anti-Siglec-15 increased long-term survival to 60% (vs. 40% with ZIKV alone), rising to 83% with anti-PD-1 treatment. Triple therapy in SB28 bearing mice yielded 76% long-term survivor rate with 1.7-fold higher CD8+ T-cell activation. Rechallenged mice showed 11-fold expansion of brain resident/effector memory CD8+ T-cells and 80% survival. Siglec-15 loss on myeloid cells enhanced phagocytosis (CT2A: 25%; SB28: 7%) and T-cell responses (activation: 81%; proliferation: 86.8%). CONCLUSION: : Targeting Siglec-15, combined with PD-1 blockade and ZIKV overcomes myeloid immunosuppression and enhances T-cell activation in GBM, promoting durable anti-tumor immunity. These findings support further investigation of this combination therapy. Siglec-15 is a protein that is expressed on glioblastoma cells and immune cells. Using fresh human tumor specimens, we identified which specific immune cells express Siglec-15. Patients whose tumors express more Siglec-15 live shorter, on average. Blocking Siglec-15 activated immune cells to kill tumor cells. Combining its blockade with a cancer-targeting virus, Zika virus, and an immunotherapy targeting PD1, mice with brain tumors lived significantly longer. These findings suggest combination therapy with blockade of Siglec-15 might be helpful for patients.
引用
- Kesarwani A, Griffith AN, Verma S, et al. Siglec-15 and PD-1 checkpoint blockade in combination with oncolytic Zika virus infection confers protection against immune-resistant gliomas. Neuro Oncol. 2026. PMID: 42572170. doi:10.1093/neuonc/noag186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。